TOPICA Reveals Phase 2 Results Of Luliconazole

TOPICA Pharmaceuticals has announced results from its phase 2 clinical study evaluating luliconazole, in patients with tinea pedis (athlete’s foot). The study was designed to assess the effectiveness of 1% luliconazole cream applied once daily for 14 days compared with once daily for 28 days.

The company said that the study met its primary efficacy endpoint demonstrating that luliconazole, when applied once daily for 14 days, was able to achieve complete clearance, as evaluated by a clear clinical score and negative mycology assessment equivalent to the 28-day dosing regimen.

The company claims that the trial evaluated the safety and optimal duration of 1% luliconazole cream administered once daily for 14 or 28 days in patients with moderate to severe tinea pedis.

Greg Vontz, president and CEO of TOPICA, said: “We are very pleased with these results, which validate our clinical development plans for luliconazole and move us one step closer toward our goal of bringing highly differentiated products to market. The encouraging mycologic results also add to our growing confidence in luliconazole and its potential to treat both tinea pedis, onychomycosis and other topical fungal infections.”

TOPICA is a specialty pharmaceutical company focused on licensing, developing and commercializing topical prescription products to treat the needs of patients with serious nail and skin conditions.